Preventing the Recurrence of Acute Pancreatitis by Alcohol and Smoking Cessation
NCT04647097 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 364
Last updated 2023-04-26
Summary
Recurrence of acute pancreatitis (AP) is often facilitated by regular alcohol consumption and smoking. An applied lifestyle intervention focusing on the cessation of alcohol consumption and smoking might prevent the recurrence of AP. REAPPEAR Study is a randomized controlled trial and a cohort study focusing on the efficacy of the lifestyle intervention and the effect of quitting alcohol and smoking respectively.
Conditions
- Acute Pancreatitis
- Recurrent Acute Pancreatitis
Interventions
- BEHAVIORAL
-
Standard intervention only
Standard intervention (SI) will be a part of standard care in all participating centers, and will be provided for all acute pancreatitis patients, who are hospitalized and their condition is alcohol induced. A specially trained study nurse will deliver the intervention, since they were found to be the most effective regarding the decrease in alcohol consumption and smoking. The cost- effectiveness of the intervention and the feasibility were also taken into account. The Assist-linked brief intervention according to the World Health Organization (WHO) will serve as the base for the intervention, with an avarage of 30 minutes, based on a review containing 69 randomized controlled trials, which concluded that longer intervention do not have additional benefit. The patients will be also educated about the disease course of acute pancreatitis during the standard intervention.
- BEHAVIORAL
-
Standard intervention plus repeated intervention
Standard intervention (SI) will be performed as described above. The repeated intervention will be delivered by the former mentioned same nurse and will be structured similarly to the standard intervention. Every visit and intervention will be individually altered according to the motivation of the patient, but they will follow the same structure. The sessions can be divided into three main parts: first, highlighting the harmful effects of smoking and alcohol on the pancreatic functions. Secondly, a discussion about the motivation of the patient will happen. The last portion of the session will focus on the responsibility of the individual to reach the desired goal will be highlighted. To enhance the efficacy of our intervention we wish to provide feed-back for the patient based on laboratory testing: the mean corpuscular volume (MCV) and gamma glutamyl-transferase (GGT) values will be measured right before the interview. The study nurse will not take part in patient care.
Sponsors & Collaborators
-
University of Pecs
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-03-01
- Primary Completion
- 2027-12-31
- Completion
- 2028-06-30
Countries
- Hungary
Study Locations
More Related Trials
-
Prognostic Value of Different Nutritional Screening Tools in Acute Pancreatitis
NCT05613673 ·Status: ACTIVE_NOT_RECRUITING
-
PancRea: Risk Factors and Outcomes of Infected Pancreatic Necrosis
NCT03253861 ·Status: COMPLETED
-
Hypertriglyceridemia Associated Acute Pancreatitis in Intensive Care Unit and Therapeutic Plasmapheresis
NCT05096455 ·Status: COMPLETED
-
Hypertriglyceridemia-associated Acute Pancreatitis: Apheresis Vs. Conservative Treatment
NCT04708925 ·Status: COMPLETED
-
Influence of Adiponutrin in Chronic Liver Disease
NCT01122797 ·Status: COMPLETED
-
Albumindialysis in Acute Pancreatitis
NCT00483912 ·Status: SUSPENDED ·Phase: NA
-
Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden.
NCT06403332 ·Status: RECRUITING ·Phase: NA
-
Neutrophil-Creatinine Index in Patients with Acute Pancreatitis: Assessment of Severity and Outcome
NCT06828965 ·Status: NOT_YET_RECRUITING
-
Predicting Acute-on-Chronic Liver Failure in Cirrhosis (PREDICT) Study
NCT03056612 ·Status: COMPLETED
-
Unknown Cause of Acute Liver Failure
NCT02041637 ·Status: COMPLETED
-
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041 ·Status: NOT_YET_RECRUITING
-
Allopurinol to Prevent Cirrhosis Related Morbidities
NCT05545670 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Prevalence of Exocrine Pancreatic Insufficiency in Patients With Decompensated Cirrhosis
NCT03236038 ·Status: COMPLETED
-
Early Rehabilitation for Severe Acute Pancreatitis (ERN-SAP)
NCT07109921 ·Status: COMPLETED ·Phase: NA
-
Efficacy of High Dose Albumin Therapy in Improving Liver Transplant-free Survival in Patients With Acute Decompensation of Cirrhosis
NCT05956197 ·Status: UNKNOWN
-
APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors
NCT02911961 ·Status: WITHDRAWN ·Phase: PHASE4
-
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
NCT03451292 ·Status: COMPLETED ·Phase: PHASE3
-
Lactated Ringers vs Normal Saline in Patients With Acute Pancreatitis: A Bias-Adjusted Meta-analysis
NCT05638555 ·Status: RECRUITING
-
Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis
NCT03364920 ·Status: UNKNOWN
-
Short-term Survival of Subjects With Acute-on-chronic Liver Failure After Plasma Exchange With Human Serum Albumin 5%
NCT03702920 ·Status: TERMINATED ·Phase: PHASE3
-
Phase Angle and Mortality in Patients With Cirrhosis
NCT02023177 ·Status: COMPLETED
-
Efficacy of Targeted And Response-Guided Albumin Therapy Versus Standard Medical Treatment In Outcomes Of Recurrent Ascites In Patients With Decompensated Cirrhosis.
NCT04679571 ·Status: UNKNOWN ·Phase: NA
-
Feasibility of an App-based Nutrition & Exercise Program in Cirrhosis
NCT05033327 ·Status: COMPLETED ·Phase: NA
-
Evaluation of the Role of Plasma Biomarkers in the Development of Decompensation in Patients With Cirrhosis .
NCT03084185 ·Status: UNKNOWN
-
Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes
NCT02791802 ·Status: UNKNOWN